Skin conditions by the numbers



  • Acne is the most common skin condition in the United States, affecting up to 50 million Americans annually.1
  • Acne usually begins in puberty and affects many adolescents and young adults.
    • Approximately 85 percent of people between the ages of 12 and 24 experience at least minor acne.2
  • Acne can occur at any stage of life and may continue into one’s 30s and 40s.3-5
    • Acne occurring in adults is increasing, affecting up to 15 percent of women.3-5
  • In 2013, the costs associated with the treatment and lost productivity among those who sought medical care for acne exceeded $1.2 billion.6
    • More than 5.1 million people sought medical treatment for acne in 2013, primarily children and young adults.6
    • The lost productivity among patients and caregivers due to acne was nearly $400 million.6

Atopic dermatitis

  • Atopic dermatitis affects nearly 28 million Americans of all ages.7
    • It affects up to 25 percent of children and 2 to 3 percent of adults.8
  • An estimated 60 percent of people with this condition develop it in their first year of life, and 90 percent develop it before age 5. However, atopic dermatitis can begin during puberty or later. 8-9
  • In 2013, the costs associated with the treatment and lost productivity among those who sought medical care for atopic dermatitis was $442 million.6
    • The total medical cost of treating atopic dermatitis was $314 million, for an average of $101.42 per treated patient.6
    • The lost productivity among patients and caregivers due to atopic dermatitis was $128 million.6

Hair loss


  • Approximately 7.5 million people in the United States have psoriasis.13
  • Psoriasis occurs in all age groups but is primarily seen in adults, with the highest proportion between ages 45 and 64.6
  • Up to 40 percent of people with psoriasis experience joint inflammation that produces symptoms of arthritis. This condition is called psoriatic arthritis.14-16
  • Approximately 80 percent of those affected with psoriasis have mild to moderate disease, while 20 percent have moderate to severe psoriasis affecting more than 5 percent of the body surface area.13
  • The most common form of psoriasis, affecting about 80 to 90 percent of psoriasis patients, is plaque psoriasis. It is characterized by patches of raised, reddish skin covered with silvery-white scale.13
  • In 2013, the total direct cost of treatment associated with psoriasis was estimated to be between $51.7 billion and $63.2 billion.6


  • Rosacea is a common skin disease that affects 16 million Americans.17-19
  • While people of all ages and races can develop rosacea, it is most common in the following groups:
    • People between age 30 and 60.20
    • Individuals with fair skin, blond hair and blue eyes.20-21
    • Women, especially during menopause.20
    • Those with a family history of rosacea.21
  • In 2013, the costs associated with the treatment and lost productivity among those who sought medical care for rosacea was $243 million.6
    • More than 1.6 million people sought treatment for rosacea in 2013.6
    • The total medical cost of treating rosacea was $165 million, for an average of $102.26 per treated patient.6
    • The lost productivity among patients and caregivers due to rosacea was $78 million.6

Skin cancer

  • Skin cancer is the most common cancer in the United States.22-23
  • It is estimated that more than 9,500 people in the U.S. are diagnosed with skin cancer every day.24-26
  • The majority of diagnosed skin cancers are NMSCs. Research estimates that NSMC affects more than 3 million Americans a year.6, 24
  • The overall incidence of BCC increased by 145 percent between 1976-1984 and 2000-2010, and the overall incidence of SCC increased 263 percent over that same period.27
    • Women had the greatest increase in incidence rates for both types of NMSC.27
    • NMSC incidence rates are increasing in people younger than 40.27
  • More than 1 million Americans are living with melanoma.28
  • It is estimated that 178,560 new cases of melanoma, 87,290 noninvasive (in situ) and 91,270 invasive, will be diagnosed in the U.S. in 2018.25-26
    • Invasive melanoma is projected to be the fifth most common cancer for men (55,150 cases) and the sixth most common cancer for women (36,120 cases) in 2018.25-26
  • Melanoma rates in the United States doubled from 1982 to 2011.23
  • Caucasians and men older than 50 have an increased risk of developing melanoma compared to the general population.25-26
  • Melanoma is the second most common form of cancer in females age 15-29.29
    • Melanoma incidence is increasing faster in females age 15-29 than in males of the same age group.30
  • Skin cancer can affect anyone, regardless of skin color.
    • Skin cancer in patients with skin of color is often diagnosed in its later stages, when it’s more difficult to treat.30-31
      • Research has shown that patients with skin of color are less likely than Caucasian patients to survive melanoma.32
    • People with skin of color are prone to skin cancer in areas that aren’t commonly exposed to the sun, like the palms of the hands, the soles of the feet, the groin and the inside of the mouth. They also may develop melanoma under their nails.31
  • On average, one American dies of melanoma every hour. In 2018, it is estimated that 9,320 deaths will be attributed to melanoma — 5,990 men and 3,330 women.25-26
  • The five-year survival rate for people whose melanoma is detected and treated before it spreads to the lymph nodes is 99 percent.25-26
  • The five-year survival rate for melanoma that spreads to nearby lymph nodes is 63 percent. The five-year survival rate for melanoma that spreads to distant lymph nodes and other organs is 20 percent.25-26
  • The annual cost of treating skin cancers in the U.S. is estimated at $8.1 billion — about $4.8 billion for NMSC and $3.3 billion for melanoma.22

1Bickers DR, Lim HW, Margolis D, Weinstock MA, Goodman C, Faulkner E et al. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. Journal of the American Academy of Dermatology 2006;55:490-500.

2Bhate K, Williams HC. Epidemiology of acne vulgaris. The British journal of dermatology 2013;168:474-85.

3Holzmann R , Shakery K. Postadolescent acne in females. Skin pharmacology and physiology 2014;27 Suppl 1:3-8.

4Khunger N , Kumar C. A clinico-epidemiological study of adult acne: is it different from adolescent acne? Indian journal of dermatology, venereology and leprology 2012;78:335-41.

5Tanghetti EA, Kawata AK, Daniels SR, Yeomans K, Burk CT , Callender VD. Understanding the Burden of Adult Female Acne. The Journal of Clinical and Aesthetic Dermatology 2014;7:22-30.

6American Academy of Dermatology/Milliman. Burden of Skin Disease. 2017.

7Adelaide HA. Review of Pimecrolimus Cream 1% for the Treatment of Mild to Moderate Atopic Dermatitis. Clinical Therapeutics. 2006; 28(12):1972-1982.

8Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014 Feb;70(2):338-51.

9Beltrani VS, Boguneiwicz M. Atopic dermatitis. Dermatol Online J 2003;9(2):1.

10Rossi A, Anzalone A, Fortuna MC, Caro G, Garelli V, Pranteda G et al. Multi-therapies in androgenetic alopecia: review and clinical experiences. Dermatologic therapy 2016;29:424-32.

11Genetics Home Reference. National Institutes of Health U.S. Library of Medicine. Accessed March 30, 2018.

12Dainichi T , Kabashima K. Alopecia areata: What’s new in epidemiology, pathogenesis, diagnosis, and therapeutic options? Journal of dermatological science 2017;86:3-12.

13Menter A, Gottlieb A, Feldman SR, Van Voorhees AS et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008 May;58(5):826-50.

14National Institutes of Health /NIAMS Info/Psoriasis/default.asp (last accessed June 1, 2013).

15National Psoriasis Foundation – (last accessed June 1, 2013).

16Gottlieb A, Korman NJ, Gordon KB, Feldman SR et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008 May;58(5):851-64

17Steinhoff, M., Schauber, J., and Leyden, J.J. New insights into rosacea pathophysiology: a review of recent findings. J Am Acad Dermatol. 2013; 69: S15–S26

18Elewski, B.E., Draelos, Z., Dréno, B., Jansen, T., Layton, A., and Picardo, M. Rosacea – global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group. J Eur Acad Dermatol Venereol. 2011; 25: 188–200

19Okhovat, J.-P. and Armstrong, A.W. Updates in rosacea: epidemiology, risk factors, and management strategies. Curr Dermatol Rep. 2014; 3: 23–28

20Rosacea. National Institute of Arthritis and Musculoskeletal and Skin Diseases.

21Abram K, Silm H, Maaroos H-I and Oona M. Risk factors associated with rosacea. Journal of the European Academy of Dermatology and Venereology. 2010; 24 (5): 565-571

22Guy GP, Machlin SR, Ekwueme DU, Yabroff KR. Prevalence and costs of skin cancer treatment in the US, 2002-2006 and 2007-2011. Am J Prev Med. 2015;48:183–7.

23Guy GP, Thomas CC, Thompson T, Watson M, Massetti GM, Richardson LC. Vital signs: Melanoma incidence and mortality trends and projections—United States, 1982–2030. MMWR Morb Mortal Wkly Rep. 2015;64(21):591-596.

24Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US population. JAMA Dermatol. Published online April 30, 2015.

25American Cancer Society. Cancer Facts and Figures 2018. Atlanta: American Cancer Society; 2018

26Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018; doi: 10.3322/caac.21442.

27Muzic, JG et al. Incidence and Trends of Basal Cell Carcinoma and Cutaneous Squamous Cell Carcinoma: A Population-Based Study in Olmstead County, Minnnesota, 2000-2010. Mayo Clin Proc. Published Online May 15, 2017.

28SEER Cancer Stat Facts: Melanoma of the Skin. National Cancer Institute. Bethesda, MD,

29NAACCR Fast Stats: An interactive quick tool for quick access to key NAACCR cancer statistics. North American Association of Central Cancer Registries. (Accessed on 3-10-2016).

30Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al (eds). SEER Cancer Statistics Review, 1975-2012, National Cancer Institute. Bethesda, MD,, based on November 2014 SEER data submission, posted to the SEER website April 2015.

31Agbai ON, Buster K, Sanchez M, Hernandez C, Kundu RV, Chiu M, Roberts WE, Draelos ZD, Bhushan R, Taylor SC, Lim HW. Skin cancer and photoprotection in people of color: a review and recommendations for physicians and the public. J Am Acad Dermatol. 2014;70(4):748-62.

32Dawes SM et al. Racial disparities in melanoma survival. J Am Acad Dermatol. 2016 Nov; 75(5):983-991.

Source link